Department of Radiology and Imaging Sciences, NIH Clinical Center, 10 Center Dr, Bldg 10, Room 1C369, MSC 1182, Bethesda, MD 20892, USA.
Radiology. 2011 Nov;261(2):375-91. doi: 10.1148/radiol.11091207.
Percutaneous ablation in the kidney is now performed as a standard therapeutic nephron-sparing option in patients who are poor candidates for resection. Its increasing use has been largely prompted by the rising incidental detection of renal cell carcinomas with cross-sectional imaging and the need to preserve renal function in patients with comorbid conditions, multiple renal cell carcinomas, and/or heritable renal cancer syndromes. Clinical studies to date indicate that radiofrequency ablation and cryoablation are effective therapies with acceptable short- to intermediate-term outcomes and with a low risk in the appropriate setting, with attention to pre-, peri-, and postprocedural detail. The results following percutaneous radiofrequency ablation and cryoablation in the treatment of renal cell carcinoma are reviewed in this article, including those of several larger scale studies of ablation of T1a tumors. Clinical and technical considerations unique to ablation in the kidney are presented, and potential complications are discussed.
经皮消融术目前已作为一种标准的保留肾单位治疗选择，适用于不适合进行切除术的患者。其广泛应用主要是由于横断面成像技术偶然发现越来越多的肾癌，以及需要在合并症、多发性肾癌和/或遗传性肾癌综合征患者中保留肾功能。迄今为止的临床研究表明，射频消融和冷冻消融是有效的治疗方法，具有可接受的短期至中期疗效，并且在适当的情况下风险较低，需要注意术前、术中和术后的细节。本文回顾了经皮射频消融和冷冻消融治疗肾癌的结果，包括几项较大规模的 T1a 肿瘤消融研究。本文介绍了肾脏消融术的独特临床和技术考虑因素，并讨论了潜在的并发症。
